Jeevan Scientific Technology Ltd (JSTL) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of Jeevan Scientific Technology Ltd ₹9.82, price ₹84.71, upside -88.4%, quality 54 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.
How to read this chart
60‑month range ₹33.91 – ₹222.75 · fair‑value band ₹7.37 – ₹12.28 · the ₹84.71 price screens above the ₹9.82 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 3, 2026.
Follow Jeevan Scientific Technology in your weekly email
Every Wednesday you see whether Jeevan Scientific Technology is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Jeevan Scientific Technology Limited engages in the clinical research and data management businesses in India.
Show more
Jeevan Scientific Technology Limited engages in the clinical research and data management businesses in India. The company's services include BA/BE studies that comprise bioanalytical and clinical services, pharmacokinetic and bio-statistics, and glucose clamping; clinical trial services, such as medical writing, clinical trial management and monitoring, drug safety, clinical data management, biostatistics and statistical programming, and quality assurance; and pharmacovigilance services, including ICSR management, aggregate safety reports, risk management plan, signal detection, medical information call center, and other integrated services. It also exports its products. The company was formerly known as Jeevan Softech Limited and changed its name to Jeevan Scientific Technology Limited in March 2011. The company was incorporated in 1999 and is based in Hyderabad, India.
Stock analysis
Jeevan Scientific Technology Ltd (JSTL) currently trades at ₹84.71, while our model-based Fair Value estimate is ₹9.82, 88.4% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of ₹24.20 per share, and 0 of the 12 models we run sit above the ₹84.71 price.
Bear case: the Earnings-Based group reads lowest at ₹4.80, and 12 of the 12 models stay below the price. Evidence for this calculation is low.
Scenario range: ₹7.37 (bear) to ₹12.28 (bull), the price of ₹84.71 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 54/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Jeevan Scientific Technology Ltd reported revenue of ₹615M in FY2025 versus ₹1.5T in FY2021, a compound −85.7%/yr. Reported net income was ₹11.5M in FY2025, compounding −91.4%/yr from FY2021.
Key figures
Market cap ₹1.7B (≈ $17.5M) · P/E ratio 44.1 · P/S ratio 0.83 · EPS (TTM) ₹1.92 · Net margin 1.9% · Return on equity 1.7% · Return on assets (EBIT) 8.2% · Operating margin 6.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 5% below its 52-week high and 139% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −88%, JSTL screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (₹4.80 to ₹48.98). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear ₹7.37Fair Value ₹9.82Bull ₹12.28
Price ₹84.71 · Upside -88.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (₹1.46 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.14/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−100.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−92.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−76.2%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−53.5%
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−63.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year−63.2%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−63.2% vs −27.6%, slowing
Compare Jeevan Scientific Technology Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 117 stocks
Beats the industry median on 5/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score54 · Below median
Fair Value upside−88.4% · Bottom 25%
Profitability
Return on equity (TTM)1.7% · Below median
Return on assets2.2% · Above median
Net margin (TTM)6.8% · Above median
Operating margin (TTM)6.8% · Above median
Growth and dividend
Revenue growth107.7% · Top 25%
Balance sheet
Debt / equity0.14× · Above median
Valuation Multiplesvs Health Information Services median · lower = cheaper
P/E (TTM)44.1× · Pricier than median
P/B2.35× · Pricier than median
P/S (TTM)2.38× · Pricier than median
EV/EBITDA11.5× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 42
PAST (return on equity)7· sector 12
HEALTH (low debt)93· sector 98
DIVIDEND (yield)0· sector 44
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Jeevan Scientific Technology Ltd (JSTL) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of ₹9.82 versus a price of ₹84.71, about −88% upside (overvalued).
What is the fair value of JSTL?
Our model-based fair value for Jeevan Scientific Technology Ltd is ₹9.82 (as of Oct 3, 2026), built from audited fundamentals. The current price: ₹84.71.
What is the quality score of JSTL?
Jeevan Scientific Technology Ltd has a Quality Score of 54/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Jeevan Scientific Technology Ltd (JSTL)?
Our model-based price target is the fair value of ₹9.82 (as of Oct 3, 2026) from 12 valuation models. Cautious scenario ₹7.37, optimistic scenario ₹12.28. It is a calculation from audited fundamentals, not an analyst target.
What is the Jeevan Scientific Technology Ltd stock forecast for 2026?
Our models put fair value at ₹9.82, about −88% upside versus a price of ₹84.71 (overvalued). Cautious scenario ₹7.37, optimistic scenario ₹12.28. The calculation is refreshed regularly with new filings.
What is the revenue of Jeevan Scientific Technology Ltd (JSTL)?
Jeevan Scientific Technology Ltd reported trailing-twelve-month revenue of about ₹710M (latest available figure, as of Oct 3, 2026).
What is the intrinsic value of Jeevan Scientific Technology Ltd (JSTL)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Jeevan Scientific Technology Ltd it is ₹9.82 per share (as of Oct 3, 2026), against a price of ₹84.71. It is the blended result of 12 valuation models (cash flow, earnings, asset, dividend).
Is Jeevan Scientific Technology Ltd stock overvalued or undervalued in 2026?
As of Oct 3, 2026, JSTL trades above its calculated fair value: price ₹84.71, fair value ₹9.82, a gap of about −88% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of JSTL?
No. The price is what the market pays today (₹84.71); the fair value is what the company's own numbers justify (₹9.82). For Jeevan Scientific Technology Ltd the two are ₹74.89 per share apart. That gap is exactly why we show both numbers side by side.
How much is Jeevan Scientific Technology Ltd worth?
The market values Jeevan Scientific Technology Ltd at about ₹1.7B (market capitalisation, as of Oct 3, 2026). Per share that is ₹84.71; our models calculate a fair value of ₹9.82 per share.
What do the bullish and bearish scenarios say about JSTL?
Our models span a range for Jeevan Scientific Technology Ltd: cautious scenario ₹7.37, base ₹9.82, optimistic ₹12.28 per share (as of Oct 3, 2026, price ₹84.71). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of JSTL?
Jeevan Scientific Technology Ltd trades at a price-to-earnings ratio of 44.1 (as of Oct 3, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹9.82 is built from several models across several years. Other multiples: P/B 2.4, P/S 2.4, EV/EBITDA 11.5.
How solid is the balance sheet of Jeevan Scientific Technology Ltd (JSTL)?
Balance-sheet figures for Jeevan Scientific Technology Ltd (as of Oct 3, 2026): return on equity 1.7%, debt of 0.14 per unit of equity. They feed the Quality Score of 54/100, which measures business quality independently of the share price.
How far is JSTL from its 52-week high?
Jeevan Scientific Technology Ltd trades at ₹84.71, about 5% below its 52-week high of ₹89.43 and 139% above the low of ₹35.49 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹9.82 is for.
Which stocks are comparable to Jeevan Scientific Technology Ltd?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, Hinge Health, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Jeevan Scientific Technology Ltd stock attractive at the current price?
The data as of Oct 3, 2026: price ₹84.71, calculated fair value ₹9.82 (−88%), Quality Score 54/100, from 12 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of JSTL calculated?
We run Jeevan Scientific Technology Ltd through 12 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹9.82, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.9 % above its aggregate fair value. Jeevan Scientific Technology Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Jeevan Scientific Technology Ltd (JSTL)?
The closing price on Oct 1, 2026 was ₹84.71. Our model-based fair value is ₹9.82, about −88% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Jeevan Scientific Technology Ltd right now?
The price sits above even our optimistic bull case (₹12.28). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (54/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Jeevan Scientific Technology Ltd
How large is the market capitalisation of Jeevan Scientific Technology Ltd (JSTL)?
The market capitalisation of Jeevan Scientific Technology Ltd is ₹1.7B (≈ $17.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Jeevan Scientific Technology Ltd (JSTL)?
The price-to-sales ratio of Jeevan Scientific Technology Ltd is 0.83 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Jeevan Scientific Technology Ltd (JSTL)?
Earnings per share at Jeevan Scientific Technology Ltd are ₹1.92 (price ÷ EPS = P/E 44.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Jeevan Scientific Technology Ltd (JSTL)?
The net margin of Jeevan Scientific Technology Ltd is 1.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Jeevan Scientific Technology Ltd (JSTL)?
The return on equity (ROE) of Jeevan Scientific Technology Ltd is 1.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Jeevan Scientific Technology Ltd (JSTL)?
On an EBIT basis the return on assets of Jeevan Scientific Technology Ltd is 8.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Jeevan Scientific Technology Ltd (JSTL)?
The operating margin of Jeevan Scientific Technology Ltd is 6.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Jeevan Scientific Technology Ltd (JSTL)?
Revenue at Jeevan Scientific Technology Ltd is growing +108% versus a year earlier (3y avg −92.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Jeevan Scientific Technology Ltd (JSTL)?
Earnings per share at Jeevan Scientific Technology Ltd are growing +24.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Jeevan Scientific Technology Ltd (JSTL) generate?
The free cash flow of Jeevan Scientific Technology Ltd is −₹77.6M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Jeevan Scientific Technology Ltd (JSTL) carry?
The net debt of Jeevan Scientific Technology Ltd is ₹76.5M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Jeevan Scientific Technology Ltd in the live analysis
One click puts Jeevan Scientific Technology Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
